Spruce Biosciences, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsSpruce Biosciences is a late-stage biopharmaceutical company developing TA-ERT, an investigational enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB), with no approved products and no revenue.
What they do
Spruce Biosciences is focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. Its lead candidate, TA-ERT, is an investigational enzyme replacement therapy administered intracerebroventricularly for MPS IIIB, a rare pediatric neurodegenerative disease. The company has no products approved for commercial sale and has not generated any product revenue to date.
Revenue drivers
- No product revenue — The company has no approved products and reported zero revenue for all quarters in 2025 and the first half of 2026.
- Collaboration income — Historically, the company received a $15.0 million upfront payment from Kaken Pharmaceutical in April 2023, contributing to reported revenue of $10.1M in 2023 and $4.9M in 2024, but no similar revenue has been reported since.
Recent performance
For the six months ended June 30, 2026, Spruce reported a net loss of $28.5 million and used $30.9 million in operating cash flow, compared to a net loss of $16.1 million and operating cash use of $21.6 million in the same period of 2025. As of June 30, 2026, the company had cash and cash equivalents of $96.3 million and an accumulated deficit of $317.7 million. The company has not generated any revenue in 2025 or the first half of 2026.
Strategy
Spruce is prioritizing the development and regulatory approval of TA-ERT for MPS IIIB. The company plans to submit a Biologics License Application (BLA) in the fourth quarter of 2026, seeking accelerated approval based on cerebrospinal fluid heparan sulfate non-reducing end (CSF HS-NRE) as a surrogate endpoint. It also plans to initiate the TrAnsform confirmatory study, a randomized, single-blind, controlled trial in children aged 1 to 5 years, in the fourth quarter of 2026. Management is strengthening leadership with recent appointments of a Chief Medical Officer and VP of Clinical Development, and has received a combined $5.5 million strategic investment from Cure Sanfilippo Foundation and National MPS Society to support patient access.
Risks
- Going concern risk — The company has stated that without additional financing, its cash as of December 31, 2025 and January 2026 debt proceeds would be insufficient to fund operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
- No approved products or revenue — Spruce has no products approved for sale and has never generated product revenue, relying entirely on external financing to fund operations.
- Regulatory and clinical uncertainty — The FDA requires the TrAnsform confirmatory study to be initiated while the BLA is under review; failure to initiate or complete it could affect potential accelerated approval.
- Significant operating losses — The company has incurred net losses every year since inception, including $39.0 million in 2025 and $28.5 million in the first half of 2026, and expects losses to continue.
Outlook
Management anticipates submitting the BLA for TA-ERT for MPS IIIB in the fourth quarter of 2026 and initiating the TrAnsform confirmatory study in the same quarter. The company believes its cash, including proceeds from the August 2026 private placement, will be sufficient to fund planned operations and development activities. Management expects to continue incurring significant and increasing losses for the foreseeable future.